distil outlook slide tool think
help investor come year roadmap
elect landscap framework valu new hc
servic model top pick upgrad
ow introduc new risk reward framework
elect still matter signpost year ahead clear
investor transform healthcar reform challeng either
parti recent stock perform six-month impli volatil signal
focu shift away election/polici chang toward earn power
next two year nine month go elect
healthcar reform like remain discuss topic expect stock
trade around key elect event super tuesday march democrat
convent june novemb elect signpost watch moreov
afford still hot button issu side aisl democrat
presid could drive chang via regulatori path area investor
focus elect get closer takeaway slide
new year new model scorecard evalu new servic compani
institut investor opportun invest futur
healthcar new digit servic model may come market like
demand fresh perspect requir investor recogn tradeoff
valu new enterpris put togeth scorecard key factor
investor consid evalu new busi model benchmark
recent ipo gross margin level consum digit
interfac emerg two metric close tie higher valuat
takeaway slide
top pick see multipl expans
opportun continu grow medicar advantag share
post close wellcar transact price target
impli upsid current
level respect stock pick support what price
witp analysi takeaway slide
also upgrad share overweight equal-weight
rais price target compani coverag
takeaway slide see exhibit summari rate
price target estim chang
conjunct outlook launch new
risk reward framework
enhanc data content analyt across
firm add context invest view
roll framework across research
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
theme elect unveil new
busi model public market
election/polici chang risk seem subsid coverag expans
afford remain key talk point
recent stock perform clear sign initi investor concern election/polici
chang fade servic coverag univers end year
under-perform bp compar bp out-performance
real stori diverg converg perform
election/polici expos stock versu less exposur sell-off
begin year fuel earli rotat manag care stock
combin initi concern potenti overarch polici chang
earn qualiti revers cours last three month year
takeaway slide insid
bellweth unit health tell stori best under-perform
bp first month year bottom octob share
ralli bp finish year bp ahead
time period combin eas concern feasibl likelihood
medicar posit commentari health insur tax hif
moreov six-month impli volatil metric suggest market expect healthcar
servic stock less volatil takeaway slide
time frame includ super tuesday march democrat
nation convent june takeaway slide
elect nine month away healthcar still poll top issu
voter democrat primari race dont expect debat dissip
use plausibl polici path guid
polici ambit like fall short practic precondit
transform polici chang repeal medicar medicar
unifi govern one parti control execut branch hous
congress low likelihood event accord current poll moreov
candid campaign big polici chang five democrat senat
doug jone d-ala bob mendez d-nj cardin d-md tom carper d-del
mark warner d-va publicli oppos medicar even unifi
govern scenario agre market seem tell us
would reach takeaway slide
medicar may reson republican side accord
convers dc consult suggest republican may
support polici expand coverag age group would
reson rust belt elector said hard predict polit
play administr chang regardless coverag
expans gain traction view posit
takeaway slide
afford continu hot button topic side aisl
democrat presid could drive chang via regulatori path area investor
focus get closer elect like absenc
unifi govern view regulatori measur aim increas
healthcar afford primari tool next administr improv
access care exampl potenti regulatori chang could includ medicar
advantag rate reduct risk adjust takeaway slide
list potenti regulatori initi implic
institut investor opportun invest
futur healthcar
last year launch healthcar disruptor seri focus role
privat compani catalyz healthcar transform although
knowledg potenti transact plausibl assum compani
morgan stanley healthcar servic disruptor list privat compani could
go public year new busi model present opportun chang
individu interact healthcar system combin technolog tradit
model emphasi meet patient wherev increas
engag lower cost ultim better outcom
scorecard investor evalu new servic model identifi key factor
consid evalu new busi model includ measur econom
valu gross margin revenu growth capit requir expand busi
model attribut end user level consum digit interfac platform vs point
solut offer benchmark recent ipo factor enrich
valuat framework gross margin level consum digit interfac
two metric close tie higher valuat base analysi six public
takeaway slide
new model combin tradit healthcar asset physician clinic
digit interact may challeng exist perspect requir investor
understand tradeoff level invest requir build digit connect
commun margin profil hybrid model valu new enterpris
qualit factor consid includ level influenc popul
total market opportun
top pick
top pick head buyer
manag care stock coverag reflect long term secular opportun
group see multipl expans opportun continu
grow medicar advantag share post-clos wellcar
transact price target impli
upsid current level respect takeaway slide
catalyst watch guidanc call medicar
advantag enrol data close wellcar deal sometim
earn full tabl catalyst see appendix slide
adjust distributor price upgrad
overweight equal-weight
part outlook adjust price target three distributor
upgrad overweight think market price
billion distributor opioid liabil minimum level liabil reflect
cardin earn call
multipl adjust reflect billion global opioid litig liabil ms base
case multipl analysi exhibit takeaway slide
conjunct upgrad share overweight
share under-perform last five year due myriad
headwind gener deflat sell side margin pressur
amazon fear regulatori concern recent
opioid liabil earn power look ahead expect specialti
busi cost cut initi support earn growth exit invest
chang dilut earn strengthen balanc sheet
ahead opioid settlement continu character environ
distributor challeng neutral group current level think
headwind discount share
stock pick support what price witp analysi conduct
ast team better understand current stock price compani
impli market expect long-term growth rate takeaway
expect
get credit long term strategi
opportun expand medicar advantag market organ
via stock rank near bottom entir
coverag univers sort market expect long term growth
ow lowest valu attribut longer term growth
almost year accord witp rank lowest among distributor
bottom coverag univers last stock like repres
uncertainti around opioid liabil think market undervalu
compani specialti opportun abil pay opioid liabil divest
stake chang healthcar next month upgrad share
ow ew updat price target impli upsid
chang rate price target estim
exhibit chang rate price target estim
pt
ep estimate compani est
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
distribut comp
ev/ebitda calcul adjust ev pv futur oper leas pmt adjust ebitda rent expens
ev/ebitda calcul adjust ev ms estimate after-tax pv futur opioid liabil
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong latin america london singapor sydney
tokyo altern may contact invest repres morgan stanley research broadway attent research manag new york ny usa
bear bull valuat
exhibit bull bear valuat
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong latin america london singapor sydney
tokyo altern may contact invest repres morgan stanley research broadway attent research manag new york ny usa
top pick
stock elect expos group manag care
drug suppli chain bp
under-perform bp ralli
outperform ye sentiment
improv market better understood low
probabl medicar outcom compani
clarifi ep trajectori legisl repeal
hif distributor perform continu
mix group bp opioid uncertainti
stock non-elect expos group hcit lab
cros/cmo outperform bp
perform peak outperform
bp contract bp year
end mainli driven
leaders/driv beneficiari drug
develop demand elect exposur
lh self help
stori activist involv
initi diverg stock expos election/polici chang
start rep jayap medicar bill
converg began investor
concern underli
fundament start eas
election/polici expos stock initi under-perform converg less expos
stock year end
stock perceiv election/polici risk
outperform year end investor sentiment eas
likelihood transform hc polici enact
hif perman remov set stage acceler
earn trajectori
thomson reuter morgan stanley research compani data
introduct propos drug rebat rule
introduct rep pramilajayap medicar bill
introduct sen berni sander medicar propos
result character higher mlrs/lower qualiti earn
result clariti earn power lead ralli
elizabeth warren releas hc plan divert pure medicar
look ahead
election/polici expos name worst volatil
may rear view mirror
month impli volatil expect elect expos name vs
volatil
spike
tension
suggest hc stock less
volatil includ
super tuesday
democrat primari
prospect realiz
volatil retrospect
elect expos group
higher
volatil expect
elect expos name
democrat primari race
begin medicar
month impli volatil divid
day realiz volatil
expos group vs
thomson reuter morgan stanley research compani data
polit catalyst point march april june month focu
march april june
increas volatil
deleg
grab march
alloc
end april
deleg
grab
democrat primari
kick februari
iowa took june
gain enough deleg
clinch nomin
septemb
final debat wrap
thing could surpris shouldnt
last five year part annual outlook brainstorm hypothet out-of-the-box
idea eight play far hypothes
make anoth transform acquisit expand
walgreen announc asset light retail strategi
amazon launch brick mortar pharmaci wholefood near
lab get repriev revers pama cut
giant consid extend ehr capabl
pe intervent nextgen and/or allscript
spin european oper
prior thought green materi
move asset-light portfolio announc
program reduc store count
doj block consolid involv govern
program medicar expans age
transit pbm ahead schedul
diplomat get immun independ
express script rejoin
amazon launch ehr
walgreen partner optum clinic
scoop
express script reintroduc hep formulari
walgreen express script get togeth
materi synergi lead lh upsid
note knowledg potenti transact manag team comment
section navig polit
base case scenario mco multipl risk
risk privat
risk
headlin risk
increas focu
risk privat insur
divid democrat government
discount
adjust reflect
averag
discount
investor expect
hillari win adjust
reflect hif repeal
averag
discount
prior implement
around impact adjust
clariti
reflect hif repeal
averag discount
reimburs rate cut adjust
period
reflect hif repeal
neutral
discount
limit uncertainti
relat healthcar agenda
level uncertainti akin
initi implement
discount adjust reflect averag multipl increas across manag care hif repeal announc
morgan stanley research estim compani data
medicar rate cut increas
scrutini
regulatori uncertainti low legisl
translat capit
new payor provid model prolif fund
payor provid
epicent privat fund
given abil influenc
member behavior spend
payor account top
privat compani look
almost fund
fund like function busi
model complex higher valuat
assign enterpris access
valuabl data abil influenc
provid receiv half
fund compar payor
lower fund like function
infrastructur requir lower
new payor provid model compris almost half top privat compani fund
fund
notabl provid model
track focus primari
commerci medicar etc
remain focus
number compani
polit compani catalyst calendar
hh file repli support cross-mot summari judgment pama
ci centen appeal louisiana medicaid contract
super tuesday part democrat deleg total grab across state
super tuesday part democrat deleg total grab across state
territori hi id mi mo ms nd oh wa
super tuesday part democrat deleg total grab across state
territori az fl il mp
polit compani catalyst calendar continu
super tuesday part democrat deleg total grab across state
territori ct de md ny pa ri
execut growth ingeniorx integr medicaid margin upsid
calcul price target appli price-to-earnings multipl base case ep
normal hif multipl reect turn discount
multipl histor trade discount average
adjust recent repeal hif turn multipl
largest commerci player
market share second largest
player medicaid exchang
helm new ceo gail
boudreaux anthem focus
improv commerci busi
protabl gain share medicar
advantag market place current
insourc pbm accret earn
posit anthem effect
compet marketplac
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ep plu
multipl
multipl reect
premium trade
peak co see strong
quarterli result yet get
benet tax reform adjust
hif repeal pbm transit exce
goal result increment enrol
gain membership growth continu base
busi pbm efcienc drive
greater pbm protability/penetr
ep plu
multipl
multipl
histor trade discount
average adjust recent
repeal hif turn multipl
transit pbm live esrx run
smooth result better penetr
capit deploy acceler non-pbm
ep plu
discount current multipl
discount current multipl
discount trade
trough last industri
price cycl adjust hif
repeal failur execut pbm transit
result lost prot opportun
view explan region hierarchi
research highest favor quintil
medicar advantag growth market
pbm transit poorli execut result
lower protabl lost member
price pressur govern
commerci busi result margin
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
multipl growth lever wcg rxadvanc execut success
calcul price target appli price-to-earnings multipl base case ep
normal hif multipl reect turn discount multipl
trade discount medicar sell
adjust repeal hif estimate turn
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
largest medicaid player
market share
pend wellcar acquisit expand
market presenc medicar
advantag fastest grow market
stand-alone wellcar outperform
suggest potenti upsid deal accret
base estim break-even
mid-single-digit accret
addit upsid opportun
insourc pbm integr
medic pharmaci benet
repeal would headwind
assign low probabl outcom
view descript risk reward theme
ep plu hif
discount multipl
discount multipl
in-lin averag discount
last year medicar
advantag take exchang stabil
see multipl growth driver
potenti headwind ceas materi
due dc gridlock medicar ramp
gap medicaid group
ep plu hif
multipl
multipl trade
discount medicar
sell adjust
repeal hif estimate turn base case
core execut medicar advantag
expans top exchang protabl
ep plu hif
multipl
multipl discount in-
line stock trade
trough last price cycl
medicar advantag fail launch
becom headwind medicar
advantag stall loss core
medicaid busi fide fail reach
texa unit state constitution
view explan region hierarchi
research highest favor quintil
deal wcg drive acceler growth
margin perform high end
rxadvanc grow big market pharmaci
wcg out-performance drive upsid
loss core medicaid contract
exchang protabl less expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
calcul price target appli price-to-earnings multipl base case ep
normal hif multipl reect premium multipl
 histor trade premium average adjust
multipl recent repeal hif estimate
high earn exposur
medicar advantag
execut organ medicaid
growth earn
medicaid provid addit growth
pipelin copmani
recent medicaid contract win la
ky underscor manag medicaid
strategi play
strong balanc sheet continu
solid cash gener lay foundat
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ep plu hif
bull case multipl reect premium
bull case multipl reect premium
multipl
multipl in-lin
premium peak
compani see strong
quarterli result get
benet tax reform adj hif repeal
increas share vertic
leverag vertic servic pbm
home health fuel margin expans
better outcom integr model
translat improv score share
ep plu hif
base case multipl reect premium
base case multipl reect premium
multipl
multipl
histor trade premium
average adjust multipl
recent repeal hif estimate
less busi exposur
commerci medicaid market segment
compar peer
sensit overal economi growth
continu outpac market result
ep plu hif adj
bear case multipl reect discount
bear case multipl reect discount
current multipl
current multipl
in-lin discount
trough last price
qualiti issu adj hif repeal
unabl maintain posit
medicar advantag group
focus grow busi
challeng price benet design
margin fail reach target
humana inc jpmorgan healthcar confer
 strateg ventur leverag footprint
enhanc valu base offer
view explan region hierarchi
research highest favor quintil
abl grow medicaid busi
rfp win tuck-in
compani abl sustain market
margin improv target rang
unabl maintain recent
improv star rate
competit medicar advantag
make growth challeng
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
margin stori near complet top-line growth come focu
calcul price target appli price-to-earnings multipl base case ep
multipl reect discount multipl line w/
stock trade reect regulatori overhang medicaid rfp loss stabil
margin discount adj hif repeal
molina fourth largest player
major revenu
market remaind revenu
deriv exchang
bring exchang top-line back pre-
restructur level addit
win new medicaid rfp key
opportun earn growth
also offer strateg option
manag care peer look fuel medicaid
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
bull case ep
bull case multipl reect discount
bull case multipl reect discount
multipl
multipl line
year average discount
adjust hif repeal
restructur save high-end guid
rang good direct new ceo
turnaround busi pick
bid addit maintain strong
base case ep
base case multipl reect discount
base case multipl reect discount
multipl
multipl discount line
w/ stock trade
rfp loss stabil margin discount
adj hif repeal restructur
save middl rang exchang loss
improv gener save
low end guid rang
restructur plan exchang loss
reduc via announc strateg exit w/
bear case ep
bear case multipl reect discount
bear case multipl reect discount
multipl
multipl discount
line trade trough
last price cycl adj
hif repeal longer turnaround
expect exchang loss continu
margin declin fail renew
recent margin expans led
unsustain compani pursu top-line
grow exchang enrol sustain
texa unit state constitution
view explan region hierarchi
research highest favor quintil
enrol grow back level
protabl margin
peer look grow medicaid
recent margin follow cost cut fail
sustain compani pursu top-line growth
margin
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
return histor growth optum epicent earn potenti
calcul price target appli price-to-earnings multipl base case ep
normal hif multipl reect turn premium
multipl histor trade premium average
adj recent repeal hif
number one
medicar advantag player
market share number two medicar
pdp player market share
number two commerci player
unit model enhanc via vertic
integr optumrx pbm platform
one three largest pbm
countri
larg lead breadth servic
offer consider exposur
govern busi well
posit potenti chang
strong balanc sheet continu
solid cash gener give exibl
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ep plu
bull case multipl reect premium
bull case multipl reect premium
multipl
multipl premium in-lin
stock trade peak
compani see strong
quarterli result yet get
benet tax reform adjust
discount repeal hif optum
becom gold standard competit
health plan optum continu expand
becom irreplac smaller
plan across pharmaci healthcar
ep plu
premium multipl
premium multipl
histor trade premium
 average adj recent
repeal hif optum growth
earn driven multipl
expans continu diversifi
strength servic offer drive double-
digit ep growth healthcar
busi integr model continu
view descript risk reward theme
ep plu
multipl
multipl discount in-
line stock trade
trough last price cycl
adj hif repeal
competit advantag optum
deterior offer gain share
mco want busi
optum margin esp optumrx
view explan region hierarchi
research highest favor quintil
growth market
optum integr lead industri lead
medicaid margin improv target
slower growth core growth area
medicar advantag commerci medicaid
focu servic
optum growth slow competitor becom
reluct work unitedhealth
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
vertic integr model w/ opp increas govern commerci share
calcul price target appli price-to-earnings multipl base case ep
normal hif multipl reect turn discount current
multipl discount in-lin stock trade sell
adjust hif repeal
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ep plu hif
current multipl
current multipl
premium in-lin stock
trade peak compani
see strong quarterli result
yet get benet tax reform
adjust hif repeal esrx
activ two compani littl
overlap drive higher expect
cash ow allow exibl
ep plu hif
discount current multipl
discount current multipl
discount in-lin stock
trade sell adjust hif
repeal acquisit esrx
bring addit new capabl
specialti pharmaci increasingli larg
portion spend beyond vertic
integr play combin expect
gener signic cash ow
help compani de-lev
fourth largest commerci
share exchang share
acquisit esrx creat vertic
integr player better abil
manag medic pharmaci spend
drive signic save member
flexibl balanc sheet deploy
opportun upsel dental vision
ancillari servic help drive acceler
opportun penetr
remain co cross sell area
view descript risk reward theme
ep plu hif
current multipl
current multipl
discount in-lin stock
trade trough last
price cycl adjust hif repeal
assum deal reach vertic
integr target oper two
separ busi unit synergi
corp earn guidanc
china india
view explan region hierarchi
research highest favor quintil
enterpris synergi ahead
capit deploy grow gov
esrx deal integr fail meet synergi
regulatori uncertainti continu weigh
pbm margin contract competit
commerci enrol growth
materi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
acquir unitedhealth
base price paid unit acquir share
last yr via seri acquisit
dplo diversi end-to-end
pbm infus center mail order
high servic level model reson
biopharma manufactur patient
translat disproportion share
combin specialti pbm
increas leverag improv
purchas econom make pbm
loss pbm contract weigh
ebitda loss specialti contract
weigh ebitda
given dplo lack scale believ
disadvantag
base price paid unit acquir
base price paid unit acquir
view descript risk reward theme
competit vertic integr
player specialti pbm busi
drive share loss contract
increas dir fees/reb guarante
view explan region hierarchi
infus ebitda margin higher
expect therefor warrant higher multipl
pbm sell season result busi
expect
delay pharma pipelin particularli ldd
reimburs risk dir fee exclus
narrow network
chang rebat polici
addit pbm contract loss specialti
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
secular headwind retail pharmaci challeng long-term ebit growth
ev/ebitda multipl adj ebitda multipl reect normal
year average wba/cv multipl exclud peak multipl unlik absent
accret strateg acquisit and/or subsid amazon threat trough
multipl disput w/ esrx concern cvs/caremark integr
multipl prefer network lead acceler growth
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
average multipl exclud histor
peak multipl unlik absent
subsid amazon threat
multipl compani benet
acceler growth prefer
network use six year averag
multipl exclud
period multipl compress
due combin compani specic
issu disput express script
assign multipl reect
exclud peak multipl
unlik absent accret strateg
acquisit and/or subsid amazon
disput
script concern
cvs/caremark integr
multipl prefer network
lead acceler growth
retail pharmaci chain us well
boot pharmaci allianc drug
distribut europ
guidanc call turnaround
core us busi deliv ebit
outlook reli improv fundament
compani control
inat front end
walgreen balanc sheet
deploy capit well
strateg option potenti
reposit portfolio asset
new strategi provid roadmap
futur growth potenti catalyst
view descript risk reward theme
multipl go
disput express script
assum benet cost save
initi synergies/stor
optim also back present
valu estim cash ow associ
potenti opioid payment
china india
view explan region hierarchi
research highest favor quintil
higher synergi store
expect save
wbad abl extract higher gener save
reimburs pressur get larger
off-set via gener procur
transform program yield lower
retail continu under-perform
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
vertic integr enterpris opp transform healthcar deliveri
pt deriv use sotp analysi assign ev/ebitda multipl
retail normal year average ev/ebitda multipl pharmaci servic
express script multipl month prior acquisit announc price-to-earnings
multipl health benet in-line w/ average ci multipl rel
 prior sell adjust hif repeal
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
combin aetna creat fulli
posit premier player
transform us healthcar
envis pivot role
reshap access health care
leverag exist real estat creat
local healthcar hub lead addit
combin aetna provid path
return earn growth
time align aetna
membership cost synergi
acceler pace debt paydown
de-lever underappreci
view descript risk reward theme
multipl repres peak
multipl compani see
share gain strong sell season
valid integr caremark busi
model health benet assum
price-to-earnings multipl base
premium unitedhealthcar trade
prior medicare-for-al sell
assign ev/ebitda multipl
retail normal year average
ev/ebitda multipl pbm
script multipl month prior
acquisit announc
price-to-earnings multipl in-line average
ci multipl rel
prior sell
adjust hif repeal assum
synergi enterpris
multipl repres trough
multipl initi /caremark
integr period assum
price-to-earnings multipl trough
aetna multipl period structur
prior assum deal synergi
enterpris modern initi
materi also back present
valu estim cash ow associ
potenti opioid payment
health corp earn guidanc
front end store sale
retail rx store sale
month premium medic loss ratio
view explan region hierarchi
research highest favor quintil
integr model drive new health plan
amazon ventur
healthcar front end comp improv
growth exce growth seen
plan buy new model
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
nt/lt share gain opp open payor contract market consolid
price-to-earnings base case ep multipl reect discount current
multipl averag year discount
largest nation
lab market share physician lab
unit decis open lab contract
establish long-term strateg
partnership two nation lab
labcorp set
stage ration price provid quest
opportun gain market share
capit deploy form tuck-in
strategi cost cut program
invigor increas test mix toward
advanc molecular diagnost
view descript risk reward theme
price-to-earnings bull case ep
bull case multipl reect premium
bull case multipl reect premium
current multipl
current multipl in-lin
price-to-earnings base case ep
base case multipl reect discount
base case multipl reect discount
current multipl
current multipl in-lin
price-to-earnings bear case ep
bear case multipl reect discount
bear case multipl reect discount
current multipl
current multipl in-lin
volum growth move in-network
bcbsnj less scale region
player well prefer lab
view explan region hierarchi
research highest favor quintil
hh le repli support cross-mot
summari judgment pama
quest diagnost inc earn guidanc
higher core volum growth faster
expect share gain region
revers pama cut
consolid driver higher benet
volum growth share gain meet
save program magnitud come
expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
risk reward laboratori corp america hold lh
lt share gain opp pref payor partnership cro faster growth
price-to-earnings base case ep multipl reect discount current
multipl lh averag year discount
labcorp second largest refer
lab compani matur industri
plan open lab
contract establish long-term strateg
partnership labcorp quest
diagnost set stage ration
price share gain opportun
posit lab rel safe haven
within hc servic sector
headwind
reimburs pressur exposur
quanti factor ms/market
cro diversi labcorp busi
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
price-to-earnings bull case ep
bull case multipl reect premium
bull case multipl reect premium
current multipl
current multipl
price-to-earnings base case ep
base case multipl reect discount
base case multipl reect discount
current multipl
current multipl
price-to-earnings bear case ep
bear case multipl reect discount
bear case multipl reect discount
current multipl
current multipl
 risk reward laboratori corp america hold lh
hh le repli support cross-mot
summari judgment pama
laboratori corpor america hold
earn guidanc
laboratori corpor america hold
volum growth less scale region
player prefer lab network
china india
view explan region hierarchi
research highest favor quintil
higher core volum growth faster
expect share gain region
revers pama cut
medicar reimburs pressur
abat revers
covanc chiltern deal synergi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
data centric strategi gain share path acceler earn growth
dcf analysi use wacc perpetu growth rate
iqvia combin cro bellweth
integr clinic expertis
technolog asset leader futur
oce gain traction provid upsid
opportun drive organ
growth toward long term goal high
cut revenu synergi
provid earn boost next year
compani posit servic
pharma manufactur longer term drug
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ev/ebitda bull case ebitda
revenu growth come ahead guid
revenu growth come ahead guid
top-line compound-annual-growth-rate
ebitda growth
synergi ramp translat
ebitda compound-annual-growth-rate
ev/ebitda base case ebitda
iqvia execut plan
iqvia execut plan top-line compound-annual-growth-rate
in-line
manag guidanc adj
ebitda growth
synergi ramp translat
ebitda compound-annual-growth-rate in-line
manag guidanc
view descript risk reward theme
ev/ebitda bear case
growth miss mark
growth miss mark top-line compound-annual-growth-rate
ebitda growth
translat
ebitda compound-annual-growth-rate
quarterli book
strateg partnership larg pharma
quarterli result focu backlog growth
view explan region hierarchi
research highest favor quintil
oce contract fail materi
integr prove challeng
potenti loss delay larg contract
strateg partnerships/deploy lead
price pressur margin deterior
oce offer translat acceler top-line
growth margin expans
substanti runway growth opportun
smart clinic trial
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
robust demand path margin expans deliv target
dcf analysi use wacc perpetu growth rate
impli price-to-earnings bull case ep
 top-line growth higher
end target termin growth
 oper margin expans
anoth bp expans
impli price-to-earnings base case ep
 top-line growth
top-line growth in-line
target rm revenu
organ growth growth
acquisit dsa revenu
organ growth ms
revenu organ growth
termin growth
 oper margin expans
given initi invest integr
expans
charl river market leader
recent acquisit expand
portfolio offer upstream expand
tradit preclin toxicolog
margin may improv cost-cut
initi new open capac
competit share may limit price
view descript risk reward theme
impli price-to-earnings bear case ep
 top-line growth miss
year growth target termin growth
 oper margin expans
given initi invest integr
cost post acquisit margin
expans
strateg agreement larg pharma
view explan region hierarchi
research highest favor quintil
research model demand decreas faster
develop growth fail materi
integr acquisit expans
discoveri outsourc prove
challeng anticip
research model demand improv time
acceler top-line growth contribut
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
gain share biolog valuat reect balanc risk-reward
base case dcf includ termin growth wacc
ev/ebitda bull case
grow lt target top-line
organ growth normal
driven
out-performance biolog trend mid-
site util revenu strength lead
annual organ ebitda margin expans
bp y/i near-term
ev/ebitda base case
organ top-line growth
medium term modest ebitda
margin expans top-line organ growth
normal
biolog specialti drug
deliveri contribut greatest dollar
y/i near-term
paragon acquisit busi mix shift
improv economi scale
largest public pure play
pharmaceut compani
compani follow molecul
manufactur formul clinic
stage commerci product
creat high level client sticki
portfolio servic align
pipelin increasingli complex molecul
reli advanc deliveri technolog
post-integr paragon cook
pharmica biolog account
revenu mix posit
view descript risk reward theme
ev/ebitda bear case
grow lt revenu target
top-line growth normal
weak softgel
trend growth
paragon biolog fail
contract normal
strateg partnership larg pharma
quarterli result focu backlog growth
view explan region hierarchi
research highest favor quintil
under-perform biolog softgel
grow lt target
manag fail capit organ
margin contract driven biopharma
meet lt target driven improv biolog
trend softgel busi
margin expans opportun paragon
new drug launch pipelin
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
lt growth depend new strateg initi partnership
dcf-deriv pt wacc medium-term growth rate termin growth
market leader global
ehr market account share
us market market alreadi
penetr greeneld opportun
hospit continu shift
spend area outsid core
popul key manag
deliv long-term top-line growth
strateg growth initi
consum employ medicaid
provid upsid option requir
increment invest outsid
cut initi expand
oper margin near-to-mid term
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
price-to-earnings multipl appli bull
price-to-earnings multipl appli bull
case ep estim
case ep estim revenu
re-acceler high singl digit due
faster-than-expect uptak revenu
offer newer offer ebitda
margin expand beyond rang
price-to-earnings multipl appli base
price-to-earnings multipl appli base
case ep estim
case ep estim revenu
grow mid-high single-digit
ebitda margin rang
price-to-earnings multipl appli bear
price-to-earnings multipl appli bear
case ep estim
case ep estim revenu
growth deceler low-single-digit
ebitda margin rang
analyst day himss
view explan region hierarchi
research highest favor quintil
faster expect ramp va contract
revenu acceler non-cor product
popul health itwork
expans hospit hcit budget
revenu deceler ebit declin
ration low-margin contract
lack traction non-cor product
implement delay va contract
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
custom renew visibl revenu acv trend support pt
multiples-bas price target assum multipl ebitda in-lin
averag ev/ebitda multipl softwar compani grow top-line
ebitda margin rang
inovalon provid cloud-bas
healthcar manag care organ
provid pharmaci life scienc
expect top-line organ growth
hsd-ldd rang contract
renew rate rang
revenu come subscript
increas visibl futur revenu
expect platform invest
oper efcienc continu drive
ebitda growth margin expans
slightli off-set invest sale
high net-debt ebitda leverag ratio
limit
view descript risk reward theme
bull case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
bull case ebitda estim
bull case ebitda estim
million revenu acceler low-double-
digit ebitda margin improv
base case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
base case ebitda estim
base case ebitda estim
million revenu growth remain mid-
high singl digit ebitda margin
remain rang
bear case ebitda
ev/ebitda multipl appli
ev/ebitda multipl appli
bear case ebitda estim
bear case ebitda estim
million revenu growth declin low-
singl digit ebitda margin remain
rang
acceler acv
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
lt growth depend veradigm acquisit off-set core declin
dcf-base price target use wacc mid-term growth termin growth
allscript diversi hcit vendor
provid market hospit physician
practic core busi
revenu veradigm payor life
scienc smaller revenu
faster-grow segment
compound-annual-growth-rate rang includ
acquisit
organ core provid market
well veradigm given
underli fundament industri
see challeng achiev growth
impli bull case ep
top-line growth rate
top-line growth rate
compani organ growth rate
compani organ growth rate
acceler contribut
acceler contribut
growth rate remain rang
organ termin
growth rate also assum
ebitda margin expand
compani achiev deal synergi
impli base case ep
top-line growth rate
top-line growth rate
compani organ growth rate
compani organ growth rate
continu rang
continu rang
add addit
add addit assum mid-
term growth rate fall organ
 termin growth
rate ebitda margin reach
rang mid-term
compani achiev deal synergi
make addit invest adjac
view descript risk reward theme
impli bear case ep
top-line growth rate
top-line growth rate
compani organ growth rate
compani organ growth rate
continu deceler partial off-set
continu deceler partial off-set
 assum mid-term growth rate
fall termin growth rate
ebitda margin fall rang
compani make invest
adjac product area
quarterli result focu book
china india
view explan region hierarchi
re-acceler provid budget spend
expans wallet share among core
greater expect contribut
increas deal synergi oper
contract provid budget
deceler veradigm revenu growth
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
increas pace invest requir sustain lt top-line growth
dcf-deriv price target assum medium-term growth rate wacc
termin growth rate
nextgen vendor softwar
servic physician ofc commun
underli market dynam continu
challeng reimburs pressur
increas cost drive custom
consolid put pressur growth
opportun earn trajectori
order align shift market
trend compani invest
integr platform solut
requir substanti invest
 reposit compani portfolio
futur top-line growth expect
result near-term headwind earn
recent acquisit expect
contribut subscript revenu
view descript risk reward theme
bull case ep
revenu growth medium-term
reect growth new acquisit
faster uptak revenu cycl manag
margin declin near-term
expand back toward long-
term bull case impli multipl line
multipl athena acquir
earli
base case ep
revenu growth medium-term
oper margin contract bp
per year due
invest follow expans back
toward long-term
bear case ep
revenu growth medium-term
oper margin contract
per year due
invest follow expans back
toward long-term
quarterli earn focu pipelin
new channel relationship hospital/hospit
continu develop new product line
new partnership veradigm
acceler book convers margin
re-acceler hcit industri spend
slower expect book convers
acceler physician practic consolid
view explan region hierarchi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
highest risk opioid liabil lowest benet specialti
dcf-deriv base case price assum termin growth wacc
addit assum global opioid litig settlement estim
respons
cardin third largest drug
distributor oper segment drug
distribut ebit medic
suppli ebit
amongst distributor cardin
lowest revenu exposur faster-
grow specialti busi cardin also
greatest risk cash ow
continu risk moder brand
renew loss custom discount
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
impli multipl averag
yr forward ev/ebitda multipl past
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
impli multipl in-lin averag
forward ev/ebitda multipl
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
impli multipl in-lin forward
ev/ebitda multipl past year
jpmorgan healthcar confer
drug price increas particularli januari
gener manufactur commentari gener
news ow opioid litig settlement
view explan region hierarchi
research highest favor quintil
increas brand inat
acceler growth specialti drug
distribut servic
signic slowdown brand inat
deterior gener price deation
continu price pressur margin eros
increas opioid legal settlement payment
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
growth specialti revenu strong balanc sheet mitig opioid risk
growth rate mid-term ebit margin wacc addit assum
global opioid litig settlement estim respons
largest distributor
pharmaceut medic suppli
estim specialti
revenu billion second largest
exposur among three distributor
segment includ faster-grow higher-
although largest
potenti liabil attribut opioid-
relat litig among distributor
believ also
strongest balanc sheet best
abil weather potenti liabil
continu risk brand drug
futur litig
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
impli ev/ebitda bull case
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
impli multipl in-lin averag
forward ev/ebitda multipl past
impli ev/ebitda base case
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
impli multipl modestli averag
forward ev/ebitda multipl past
impli ev/ebitda bear case
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
impli multipl in-lin minimum
forward ev/ebitda multipl past
mckesson corp jpmorgan healthcar confer
drug price increas particularli januari
gener manufactur commentari gener
news ow opioid litig settlement
view explan region hierarchi
research highest favor quintil
increas brand inat
acceler growth specialti drug
distribut servic
reimburs headwind europ abat
signic slowdown brand inat
deterior gener price deation
continu price pressur margin eros
increas opioid legal settlement payment
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
larg under-penetrated support strong top-line growth next yr
pt impli base case revenu estim million
multipl in-lin averag ev/rev multipl high-growth saa
healthcar compani grow top-line per year gross margin low
livongo market leader diabet
platform rst-mover advantag
posit well take share
adjac hypertens
expand jumbo employ
market could open increment
address diabet patient
relationship channel partner
support livongo
addit upsid opportun
expans new payor market includ
medicar advantag full-risk
cross-sel product includ
hypertens weight manag
view descript risk reward theme
impli revenu estim
ev multipl appli bull
ev multipl appli bull
case revenu estim mn
case revenu estim mn
revenu growth driven acceler rate
new client add particularli within
commerci aso diabet market well
add lead faster member add
success cross-sel hypertens
impli revenu estim
ev multipl appli
ev multipl appli
base case revenu estim
base case revenu estim
mn mn revenu growth driven expand
sign new commerci aso client
expans new payor market
cross-sel hypertens
impli revenu estim
ev multipl appli bear
ev multipl appli bear
case revenu estim mn
case revenu estim mn
revenu growth deceler livongo
incur difculti penetr new
commerci aso client expand
stall membership growth limit cross-
jpmorgan healthcar confer
quarterli earn earn
view explan region hierarchi
research highest favor quintil
acceler growth new non-diabet
acceler entri payor vertic
medicar advantag feder full-risk
high concentr revenu
channel partner one
product
healthplan
could develop offer eat
market opportun
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
acquir centen
acquisit price
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
offer purchas wcg
acquir wcg per share
offer purchas wcg
acquir wcg per share
wellcar plan well-posit
fast grow govern market
plan medicar part
recent acquisit univers
presenc medicar well increas
access highli rate star plan
view descript risk reward theme
cnc/wcg deal break growth
meridian synergi fail materi
wcg lose slight share medicar
advantag medicaid busi also
slow modestli multipl equal
averag overal growth
slower
view explan region hierarchi
research highest favor quintil
 either medicaid medicar
deal fail close/clos later
aggress price core medicaid
medicar busi lead either share loss
reduc protabl
meridian deal synergi fail materi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
market leader specialti balanc risk-reward
wacc addit assum global opioid litig settlement
estim respons
second largest
drug wholesal us largest
specialti distributor posit benet
grow specialti pipelin
among distributor
highest revenu exposur higher-growth
higher-margin specialti
opioid liabil continu
distribut agreement
walgreen largest custom provid
compani long term revenu
visibl sourc benet
greater scrutini brand inat
pharmedium limit new product
introduct like continu weigh
growth prole forseeabl futur
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
ebitda excl opioid
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
ebitda excl opioid
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
ebitda excl opioid
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
jpmorgan healthcar
drug price increas particularli januari
gener manufactur commentari gener
news ow opioid litig settlement
increas brand inat
acceler growth specialti drug
distribut servic
signic slowdown brand inat
deterior gener price deation
continu price pressur margin eros
increas opioid legal settlement payment
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
ebit ebitda
depreci amort
cog revenu
dsg revenu
 revenu
oper expens revenu
tax pre-tax incom
good sold
equiti loss affili
interest expens
net incom continu oper
loss incom attribut nci
non-gaap net incom
good sold
net incom continu oper
loss incom attribut nci
non-gaap net incom
servic
gener administr expens
amort intang
invest incom incom
goodwil intang impair
incom continu oper
 revenu
servic
tax rate hif
net incom continu oper
million
less revenu
less sale client servic
sale client servic
support mainten
sell gener administr
amort intang
incom continu oper
loss incom discontinu oper
ebit ebitda
depreci amort
net incom cont op non-gaap
sale
amort intang
good sold
gains-to-loss sale secur
sale
sell gener administr expens
depreci amort
incom oper restructur
incom oper
loss extinguish debt
incom incom tax equiti nci
incom equiti earn nci
equiti earn unconsolid affili
net loss incom attribut nci
net incom attribut iqvia
adjust ebit ebitda
depreci amort
ebit restructur impair
sale
million
share use ep calc
servic revenu
provis incom tax
reconcili non-
amort net tax
adj incom continu oper
depreci amort cash flow statement
provis incom tax
 revenue
 revenu
premium tax premium
tax rate fee
million
softwar hardwar non-recur
good sold
amort acquir intang asset
impair goodwil asset
provis tax
expens sale
softwar hardwar non-recur
